Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Research for Efficacy and Safety of Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission

NCT05596097 is registered in ClinicalTrials.gov with LanZhou University as lead sponsor.

NCT NCT05596097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05596097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Research for Efficacy and Safety of Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission
Lead sponsor
LanZhou University
Phase
Phase 2
Overall status
Unknown status
Start date
October 30, 2022
Completion date
July 30, 2026
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma (dlbcl)